The efficacy of Covaxin which is co-developed by Bharat Biotech International and the Indian Council of Medical Research has been found to be 81 per cent. With this, the mercury level of western Big pharma companies has shot up. They can’t stand the fact that India’s home grown vaccine is cheaper and easier to store and transport than any other vaccines present in the global market.
Faheem Younus, a U.S based MD, who backs the interests of western Big Pharma, was triggered by the efficacy resuts and tweeted “Vaccine efficacy data is published- not announced.”
Unlike usual protocol, most major COVID19 vaccine manufacturers (Pfizer, Moderna, AstraZeneca…) have announced phase 3 interim results through press releases. Publications have followed after weeks/months. Hoping to see @BharatBiotech publication soon. https://t.co/ZktOOYC2UO
— Prof Shamika Ravi (@ShamikaRavi) March 3, 2021
But before Faheem would have planted the seeds of doubt in the minds of common people regarding the Indian vaccine, Prof. Shamika Ravi thrashed his claims and tweeted befittingly, “most major COVID19 vaccine manufacturers (Pfizer, Moderna, Astrazeneca…) have announced phase 3 interim results through press releases. Publications have followed after weeks/months.
The usual rant against India’s prowess in vaccine manufacturing and immunisation drives is not new. It is not very surprising that as India rises higher in the pharmaceuticals sector and helps the world lift itself out of the pandemic, western manufacturers will have trouble digesting it. The tremendous success in India’s vaccine drive should be credited to Indian scientists, chemists and the whole Indian administration, as they have created the best vaccine available till date. Best in quality. Best in price. And Best in compatibility.
Moderna costs around $32 to $37 and Bharat Biotech’s Covaxin costs merely 3$ to 5$. When we talk about compatibility, Covaxin is more storage friendly than other vaccines. For instance Pfizer needs to be kept in extremely cold temperatures of minus 70 degrees Celsius, the cost of which may go into billions, whereas Covaxin requires only minus 2-8 degrees Celsius cold chain which is much more viable for warm, developing and underdeveloped nations. By the above comparison the reason behind the success of ‘Vaccine Maitri’ is evident.
Bloomberg reported on the development in a report titled, ‘Criticized Indian Vaccine Already in Use Found 81% Effective.’ The heartache was real because many western publications have attacked India’s vaccines in a bid to slander them. India, the biggest vaccine manufacturer, has trumped all in terms of vaccine diplomacy and even back home, its vaccination drive is in full swing.
Western Pharma companies hardly care about catering to the needs of poorer African nations or Southeast Asian countries. Their focus is on ripping off developed, rich economies with overpriced drugs and vaccine doses. However, this time, as Moderna and Pfizer failed to deliver vaccines to Canada on time, India filled the vacuum and demonstrated to the North American continent that Indian Pharma is far more reliable.
TFIPOST has earlier reported how media publications in favour of western Big Pharma downplayed Hydroxychloroquine in comparison to Remdesivir amid the CoronaviruspPandemic. As a matter of fact the countries which consumed HCQ as an initial treatment for Covid have low death rates than the countries which used Remdesivir and moreover, HCQ is a generic drug exported across the world by India which manufactures over 70% of the world’s HCQ.